Should You Buy Vaxart in April?

Should You Buy Vaxart in April?

This is especially true in the biotech world, where data from a clinical trial can be the difference between billions in revenue or auctioning off scraps of intellectual property. Vaxart (NASDAQ: VXRT) has already experienced this boom-and-bust cycle in 2021. If Vaxart can prove investors wrong, the stock may be back near all-time highs by summer.